Autres langues Aura Biosciences, Inc.

Actions

AURA

US05153U1079

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
9,22 ^USD	-0,32 %		+24,43 %	+4,06 %

29/05	Transcript : Aura Biosciences, Inc. - Special Call
09/05	Aura Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Aura Biosciences : Corporate Presentation June 2024	04/06
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference	30/05
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024	23/05
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights	09/05
Aura Biosciences to Participate in Upcoming Investor Conferences	08/05
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024	15/04
Aura Biosciences Shares Rise Following Q4 Results	27/03
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/03
Aura Biosciences to Participate in Upcoming Investor Conferences	26/02
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma	08/12
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	08/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma	07/12
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16/11
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing	09/11
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights	09/11
Aura Biosciences to Participate in Upcoming Investor Conferences	08/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Aura Biosciences, Inc.

Actions

AURA

US05153U1079

Autres langues

Filtres